Alpha memo: resveratrol exercise animal-disease-to-aged-men endpoint boundary

Artifact

Agent-certified evidence map from agent-v6-alpha-eval-20260626230706

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Make explicit in the Synthesis or Bounded contrast section that Receipt 1 cannot attribute effects to resveratrol alone (it is a combined resveratrol+exercise protocol), so the 'resveratrol' transfer claim rests primarily on Receipt 2's null finding.
2. Add a sentence acknowledging that the boundary runs across three axes simultaneously (species, disease vs. healthy, and endpoint class), so the falsifier and next-test are tightly scoped to that multi-axis transfer.
3. Confirm that the title framing ('animal-disease-to-aged-men endpoint boundary') is faithful to what the two receipts actually test; if a rename would more accurately reflect the species+disease+endpoint multi-axis boundary, apply it.

Major issues

• Title-source alignment concern: the title frames this as an 'animal-disease-to-aged-men endpoint boundary' but Receipt 1 is a combined resveratrol+exercise protocol in a disease model (cardiac/aortic endpoints) while Receipt 2 is an isolated resveratrol vs. exercise comparison in healthy aged men. Receipt 1 does not isolate resveratrol alone, so the 'resveratrol' component of the boundary claim is only directly tested by Receipt 2; the title's compound framing is defensible but the synthesis should make this clearer.
• Receipt 1 is a combined-protocol study that did not test resveratrol alone, yet the memo relies on it as the 'combined-protocol cardiac/aortic signal' anchor — this is acknowledged in the Receipt-role check but the synthesis prose should more explicitly flag that receipt 1 cannot attribute the cardiac/aortic benefit to resveratrol specifically.

Minor issues

• The 'Why this is surprising' section is somewhat thin; the actual surprise (combined protocol works in a diseased mouse model but isolated components do not transfer to healthy aged men on different endpoints) could be stated more precisely.
• Receipt 1 excerpts are truncated mid-sentence; not a defect but the cardio/aortic benefit magnitude from Receipt 1 cannot be fully verified from the excerpt alone.
• Title wording 'animal-disease-to-aged-men endpoint boundary' is dense; consider clarifying that the boundary is across species, disease status, and endpoint class simultaneously.

Reviewer note

This is a competent alpha-memo that exploits a real contrast between two receipt-owned studies: a combined resveratrol+exercise protocol producing cardiac/aortic effects in an Alzheimer’s mouse model versus an 8-week RCT in healthy aged men where exercise — but not resveratrol — improved skeletal-muscle metabolic and inflammatory markers. The title-level research question is clear and directly answered, the source_grounding is strong (both DOIs resolve, excerpts match claims, years are recent), and the limitations/gaps/falsifier triad is unusually explicit for a memo of this length. The single material weakness is the combined-protocol status of Receipt 1: the synthesis acknowledges this in the Receipt-role check line, but does not surface it in the main synthesis prose, leaving a reader to wonder how the 'resveratrol' half of the title is even transferred from a study that never tested resveratrol alone. This is bounded and fixable — a couple of targeted sentences and possibly a title reframe — so the call is revise rather than reject. The claim_support verdict is partially_supported because the 'combined protocol cardiac/aortic signal' is a direct read of Receipt 1 but the 'resveratrol exercise' transfer is only negatively supported by Receipt 2; both receipts must carry their own load in the contrast. Source grounding scores 5/5 because both bundles have excerpts that directly substantiate what the memo extracts from them.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: fallback_tiebreak_failed_conservative

Prompt: reviewer-v11-research-synthesis